These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38239109)

  • 1. Mpox in Children: 3 Cases.
    Frantzis I; Ungar SP; Soma VL; Knutsen D; Mazo D; Zucker J
    Pediatrics; 2024 Jan; 153(2):. PubMed ID: 38239109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022.
    Contag CA; Mische L; Fong I; Karan A; Vaidya A; McCormick DW; Bower W; Hacker JK; Johnson K; SanJuan P; Crebbin L; Temmins C; Sahni H; Bogler Y; Cooper JD; Narasimhan S
    Emerg Infect Dis; 2023 Dec; 29(12):2520-2523. PubMed ID: 37856215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Distribution of Tecovirimat During the Peak of the Mpox Outbreak - Los Angeles County, June 2022-January 2023.
    O'Neil MJ; Archer R; Danza P; Fisher R; Bagwell DA; Younis I; Kulkarni S; Rubin Z; Kim M; Balter S; Terashita D; Kim J; Singhal R; Hancz D; Gausche-Hill M; Shah NK
    MMWR Morb Mortal Wkly Rep; 2024 Jun; 73(24):546-550. PubMed ID: 38900699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential.
    Russo AT; Grosenbach DW; Honeychurch KM; Long PG; Hruby DE
    Expert Rev Anti Infect Ther; 2023 Mar; 21(3):235-242. PubMed ID: 36728515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Pilot of an Mpox Severity Scoring System.
    Zucker J; McLean J; Huang S; DeLaurentis C; Gunaratne S; Stoeckle K; Glesby MJ; Wilkin TJ; Fischer W; Damon I; Brooks JT
    J Infect Dis; 2024 Mar; 229(Supplement_2):S229-S233. PubMed ID: 37956401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mpox in the New York metropolitan area, Summer 2022.
    Gnanaprakasam R; Keller M; Glassman R; El-Khoury MY; Chen DS; Feola N; Feldman J; Chaturvedi V
    J Med Virol; 2023 Apr; 95(4):e28699. PubMed ID: 36951318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Healing Corneal Ulcer and Uveitis Following Monkeypox Disease: Diagnostic and Therapeutic Challenges.
    Androudi S; Kaufman AR; Kouvalakis A; Mitsios A; Sapounas S; Al-Khatib D; Schibler M; Pineda R; Baglivo E
    Ocul Immunol Inflamm; 2024 Apr; 32(3):253-258. PubMed ID: 37140328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical considerations on monkeypox antiviral medications: An overview.
    Pourkarim F; Entezari-Maleki T
    Pharmacol Res Perspect; 2024 Feb; 12(1):e01164. PubMed ID: 38149674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mpox Genital Lesions: A Large Single-center Experience With Intermediate Follow-up.
    Lee J; McLean J; Zucker J; Brandes S; Joice G
    J Urol; 2023 Sep; 210(3):510-516. PubMed ID: 37294043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort study.
    Fink DL; Callaby H; Luintel A; Beynon W; Bond H; Lim EY; Gkrania-Klotsas E; Heskin J; Bracchi M; Rathish B; Milligan I; O'Hara G; Rimmer S; Peters JR; Payne L; Mody N; Hodgson B; Lewthwaite P; Lester R; Woolley SD; Sturdy A; Whittington A; Johnson L; Jacobs N; Quartey J; Ai Payne B; Crowe S; Elliott IA; Harrison T; Cole J; Beard K; Cusack TP; Jones I; Banerjee R; Rampling T; ; Dunning J
    Lancet Infect Dis; 2023 May; 23(5):589-597. PubMed ID: 36566771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mpox in Children and Adolescents: Epidemiology, Clinical Features, Diagnosis, and Management.
    Beeson AM; Haston J; McCormick DW; Reynolds M; Chatham-Stephens K; McCollum AM; Godfred-Cato S
    Pediatrics; 2023 Feb; 151(2):. PubMed ID: 36471498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Tecovirimat Treatment for Mpox Disease Among People With HIV.
    Aldred B; Lyles RH; Scott JY; Gromer DJ; Aldredge A; Workowski KA; Wiley Z; Titanji BK; Szabo B; Sheth AN; Rebolledo PA; Nguyen ML; Marconi VC; Kelley CF; Kandiah S; Kalapila A; Jacob JT; Hall B; Colasanti JA; Cartwright EJ; Cantos VD
    JAMA Intern Med; 2024 Mar; 184(3):275-279. PubMed ID: 38190312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation and early outcomes of a telehealth visit model to deliver tecovirimat for mpox infection in New York City.
    Chan J; DiTullio DJ; Pagan Pirallo P; Foote M; Knutsen D; Kottkamp AC; McPherson TD; Mukherjee V; Pitts R; Wallach A; Wong M; Mazo D; Mgbako O
    J Telemed Telecare; 2023 Aug; ():1357633X231194796. PubMed ID: 37632124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mpox (Monkeypox) Infection During Pregnancy.
    Sampson MM; Magee G; Schrader EA; Dantuluri KL; Bukhari A; Passaretti C; Temming L; Leonard M; Philips JB; Weinrib D
    Obstet Gynecol; 2023 May; 141(5):1007-1010. PubMed ID: 36928418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trifluridine for treatment of mpox infection in drug combinations in ophthalmic cell models.
    Cinatl J; Bechtel M; Reus P; Ott M; Rothweiler F; Michaelis M; Ciesek S; Bojkova D
    J Med Virol; 2024 Jan; 96(1):e29354. PubMed ID: 38180134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A global update of mpox (monkeypox) in children.
    Sam-Agudu NA; Martyn-Dickens C; Ewa AU
    Curr Opin Pediatr; 2023 Apr; 35(2):193-200. PubMed ID: 36809304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report: atypical presentation of mpox with massive hematochezia and prolonged viral shedding despite tecovirimat treatment.
    Shin SU; Jung Y; Kim SE; Kim DM
    BMC Infect Dis; 2024 Feb; 24(1):183. PubMed ID: 38342913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations.
    Frenois-Veyrat G; Gallardo F; Gorgé O; Marcheteau E; Ferraris O; Baidaliuk A; Favier AL; Enfroy C; Holy X; Lourenco J; Khoury R; Nolent F; Grosenbach DW; Hruby DE; Ferrier A; Iseni F; Simon-Loriere E; Tournier JN
    Nat Microbiol; 2022 Dec; 7(12):1951-1955. PubMed ID: 36344621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tecovirimat for the treatment of severe Mpox in Germany.
    Hermanussen L; Brehm TT; Wolf T; Boesecke C; Schlabe S; Borgans F; Monin MB; Jensen BO; Windhaber S; Scholten S; Jordan S; Lütgehetmann M; Wiesch JSZ; Addo MM; Mikolajewska A; Niebank M; Schmiedel S
    Infection; 2023 Oct; 51(5):1563-1568. PubMed ID: 37273167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging pharmacological strategies for treating and preventing mpox.
    Grosenbach DW; Russo AT; Blum ED; Hruby DE
    Expert Rev Clin Pharmacol; 2023; 16(9):843-854. PubMed ID: 37592723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.